Please try another search
For the nine months ended 30 September 2017, Orexigen Therapeutics, Inc. revenues increased from $19.8M to $61.4M. Net loss totaled $120.4M vs. income of $85K. Revenues reflect Net product sales increase from $8.2M to $61M. Net loss reflects General and administrative -others increase of 79% to $127.2M (expense), Change in fair value of financial instru decrease from $17.7M (income) to $22.7M (expense).
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 18.9 | 23.36 | 19.14 | 13.88 |
Gross Profit | 14.87 | 16.51 | 12.96 | 9.61 |
Operating Income | -22.76 | -41.99 | -41.53 | -24.66 |
Net Income | -20.83 | -30.52 | -69.09 | -24.61 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 183.75 | 190 | 236.38 | 304.59 |
Total Liabilities | 242.77 | 228.69 | 240.9 | 244.2 |
Total Equity | -59.02 | -38.69 | -4.51 | 60.39 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -106.34 | -90.06 | -49.94 | -109.71 |
Cash From Investing Activities | 73.12 | 48.12 | 48.09 | -107.06 |
Cash From Financing Activities | -13.84 | -13.93 | -13.97 | 154.56 |
Net Change in Cash | -46.92 | -55.83 | -15.84 | -62.93 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review